^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NLRC5 mutation

    i
    Other names: NLRC5, NLR Family CARD Domain Containing 5, CLR16.1, NOD27, Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat And CARD Domain Containing 5, Nucleotide-Binding Oligomerization Domain Protein 4, Caterpiller Protein 16.1, NOD-Like Receptor C5, Protein NLRC5, NOD4, Nucleotide-Binding Oligomerization Domain Protein 27, Nucleotide-Binding Oligomerization Domains 27
    Entrez ID:
    84166
    Related biomarkers:
    Expression
    over2years
    Comprehensive Molecular Profiling of Colorectal Cancer With Situs Inversus Totalis by Next-Generation Sequencing. (PubMed, Front Oncol)
    Additionally, differences in the targeted genomic profiles and base substitution patterns were observed between the two groups. These findings comprehensively revealed a molecular characterization of SCRC, which will contribute to the development of personalized therapy and improved clinical management of SCRC patients.
    Journal • Next-generation sequencing • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • GNAQ (G Protein Subunit Alpha Q) • SMAD4 (SMAD family member 4) • CHEK2 (Checkpoint kinase 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • NLRC5 (NLR Family CARD Domain Containing 5) • LATS2 (Large Tumor Suppressor Kinase 2)
    |
    TP53 mutation • KRAS mutation • CHEK2 mutation • LATS2 mutation • NLRC5 mutation
    almost3years
    Mutations in transcriptional activators of MHC I antigen presentation, NLRC5 and CIITA, are mutually exclusive and have different effects on melanoma gene transcripts (AACR 2022)
    The impact of these alterations may result in varied clinical responses to ICB therapies. The landscape of these alterations needs to be further delineated to understand how tumors are directly evading class I-mediated recognition and elimination.
    IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • B2M (Beta-2-microglobulin) • NCAM1 (Neural cell adhesion molecule 1) • NLRC5 (NLR Family CARD Domain Containing 5)
    |
    NLRC5 mutation